Human copper-containing amine oxidases in drug design and development

dc.contributor.authorSerhii Vakal
dc.contributor.authorSirpa Jalkanen
dc.contributor.authorKäthe M. Dahlström
dc.contributor.authorTiina A. Salminen
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id46859756
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/46859756
dc.date.accessioned2022-10-27T11:52:01Z
dc.date.available2022-10-27T11:52:01Z
dc.description.abstract<p>Two members of the copper-containing amine oxidase family are physiologically important proteins: (1) Diamine oxidase (hDAO; AOC1) with a preference for diamines is involved in degradation of histamine and (2) Vascular adhesion protein-1 (hVAP-1; AOC3) with a preference for monoamines is a multifunctional cell-surface receptor and an enzyme. hVAP-1-targeted inhibitors are designed to treat inflammatory diseases and cancer, whereas the off-target binding of the designed inhibitors to hDAO might result in adverse drug reactions. The X-ray structures for both human enzymes are solved and provide the basis for computer-aided inhibitor design, which has been reported by several research groups. Although the putative off-target effect of hDAO is less studied, computational methods could be easily utilized to avoid the binding of VAP-1-targeted inhibitors to hDAO. The choice of the model organism for preclinical testing of hVAP-1 inhibitors is not either trivial due to species-specific binding properties of designed inhibitors and different repertoire of copper-containing amine oxidase family members in mammalian species. Thus, the facts that should be considered in hVAP-1-targeted inhibitor design are discussed in light of the applied structural bioinformatics and structural biology approaches.</p>
dc.identifier.eissn1420-3049
dc.identifier.jour-issn1420-3049
dc.identifier.olddbid172402
dc.identifier.oldhandle10024/155496
dc.identifier.urihttps://www.utupub.fi/handle/11111/30175
dc.identifier.urlhttps://www.mdpi.com/1420-3049/25/6/1293
dc.identifier.urnURN:NBN:fi-fe2021042821439
dc.language.isoen
dc.okm.affiliatedauthorJalkanen, Sirpa
dc.okm.discipline1182 Biochemistry, cell and molecular biologyen_GB
dc.okm.discipline317 Pharmacyen_GB
dc.okm.discipline1182 Biokemia, solu- ja molekyylibiologiafi_FI
dc.okm.discipline317 Farmasiafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherMDPI AG
dc.publisher.countrySwitzerlanden_GB
dc.publisher.countrySveitsifi_FI
dc.publisher.country-codeCH
dc.relation.doi10.3390/molecules25061293
dc.relation.ispartofjournalMolecules
dc.relation.issue6
dc.relation.volume25
dc.source.identifierhttps://www.utupub.fi/handle/10024/155496
dc.titleHuman copper-containing amine oxidases in drug design and development
dc.year.issued2020

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
molecules-25-01293.pdf
Size:
13.86 MB
Format:
Adobe Portable Document Format
Description:
Publisher's PDF